


Form PTO-1449
REV. 8-83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.
270-US-NEW

SERIAL NO.
09/594,978



INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:

Elan Pharmaceuticals, Inc.

FILING DATE
06/15/00

GROUP
1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
<i>JS</i>	P1 4709010	11/24/87	Holzemann	530	323	10/18/85
	P2					
	P3					
	P4					
	P5					
	P6					
	P7					
	P8					
	P9					
	P10					
	P11					

RECEIVED
DEC 20 2001
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>JS</i>	F1	WO 97/30072	8/27/97	WIPO				
	F2							
	F3							
	F4							
	F5							

OTHER PUBLICATIONS (including Author, Title, Date, Pertinent Pages, Etc.)

<i>JS</i>	D1	Majer, Pavel, et al., "Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors" <i>Protein Science</i> , 6:1458-1466 (1977).
	D2	

EXAMINER

David L. L...

DATE CONSIDERED

6/21/02

EXAMINER

Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.